Immuno-Oncology Add-On Trials: More May Not Be Better, US FDA Cautions

 
• By Michael McCaughan
immuno-oncology
It's not a principle that we have to repeat a mistake, Richard Pazdur said. • Source: Shutterstock

More from Clinical Trials

More from R&D